FXYD5
FXYD5 (FXYD domain containing ion transport regulator 5) هوَ بروتين يُشَفر بواسطة جين FXYD5 في الإنسان.[1]
الوظيفة
هذا القسم فارغ أو غير مكتمل. ساهم في توسيعه. (يوليو 2018) |
الأهمية السريرية
هذا القسم فارغ أو غير مكتمل. ساهم في توسيعه. (يوليو 2018) |
المراجع
- ^ "Entrez Gene: FXYD5 FXYD domain containing ion transport regulator 5". مؤرشف من الأصل في 2010-12-05.
قراءة متعمقة
- Nam JS، Hirohashi S، Wakefield LM (أكتوبر 2007). "Dysadherin: a new player in cancer progression". Cancer Letters. ج. 255 ع. 2: 161–9. DOI:10.1016/j.canlet.2007.02.018. PMC:2094007. PMID:17442482.
- Adams MD، Kerlavage AR، Fleischmann RD، Fuldner RA، Bult CJ، Lee NH، Kirkness EF، Weinstock KG، Gocayne JD، White O (سبتمبر 1995). "Initial assessment of human gene diversity and expression patterns based upon 83 million nucleotides of cDNA sequence" (PDF). Nature. ج. 377 ع. 6547 Suppl: 3–174. PMID:7566098. مؤرشف من الأصل (PDF) في 2016-03-04.
- Sweadner KJ، Rael E (أغسطس 2000). "The FXYD gene family of small ion transport regulators or channels: cDNA sequence, protein signature sequence, and expression". Genomics. ج. 68 ع. 1: 41–56. DOI:10.1006/geno.2000.6274. PMID:10950925.
- Zhang QH، Ye M، Wu XY، Ren SX، Zhao M، Zhao CJ، Fu G، Shen Y، Fan HY، Lu G، Zhong M، Xu XR، Han ZG، Zhang JW، Tao J، Huang QH، Zhou J، Hu GX، Gu J، Chen SJ، Chen Z (أكتوبر 2000). "Cloning and functional analysis of cDNAs with open reading frames for 300 previously undefined genes expressed in CD34+ hematopoietic stem/progenitor cells". Genome Research. ج. 10 ع. 10: 1546–60. DOI:10.1101/gr.140200. PMC:310934. PMID:11042152.
- Omasa T، Chen YG، Mantalaris A، Wu JH (يناير 2001). "A cDNA from human bone marrow encoding a protein exhibiting homology to the ATP1gamma1/PLM/MAT8 family of transmembrane proteins". Biochimica et Biophysica Acta. ج. 1517 ع. 2: 307–10. DOI:10.1016/S0167-4781(00)00251-7. PMID:11342114.
- Ino Y، Gotoh M، Sakamoto M، Tsukagoshi K، Hirohashi S (يناير 2002). "Dysadherin, a cancer-associated cell membrane glycoprotein, down-regulates E-cadherin and promotes metastasis". Proceedings of the National Academy of Sciences of the United States of America. ج. 99 ع. 1: 365–70. DOI:10.1073/pnas.012425299. PMC:117566. PMID:11756660.
- Sato H، Ino Y، Miura A، Abe Y، Sakai H، Ito K، Hirohashi S (سبتمبر 2003). "Dysadherin: expression and clinical significance in thyroid carcinoma". The Journal of Clinical Endocrinology and Metabolism. ج. 88 ع. 9: 4407–12. DOI:10.1210/jc.2002-021757. PMID:12970317.
- Shimada Y، Yamasaki S، Hashimoto Y، Ito T، Kawamura J، Soma T، Ino Y، Nakanishi Y، Sakamoto M، Hirohashi S، Imamura M (أبريل 2004). "Clinical significance of dysadherin expression in gastric cancer patients". Clinical Cancer Research. ج. 10 ع. 8: 2818–23. DOI:10.1158/1078-0432.CCR-0633-03. PMID:15102690.
- Shimada Y، Hashimoto Y، Kan T، Kawamura J، Okumura T، Soma T، Kondo K، Teratani N، Watanabe G، Ino Y، Sakamoto M، Hirohashi S، Imamura M (2004). "Prognostic significance of dysadherin expression in esophageal squamous cell carcinoma". Oncology. ج. 67 ع. 1: 73–80. DOI:10.1159/000080289. PMID:15459499.
- Shimamura T، Yasuda J، Ino Y، Gotoh M، Tsuchiya A، Nakajima A، Sakamoto M، Kanai Y، Hirohashi S (أكتوبر 2004). "Dysadherin expression facilitates cell motility and metastatic potential of human pancreatic cancer cells". Cancer Research. ج. 64 ع. 19: 6989–95. DOI:10.1158/0008-5472.CAN-04-1166. PMID:15466191.
- Wu D، Qiao Y، Kristensen GB، Li S، Troen G، Holm R، Nesland JM، Suo Z (2005). "Prognostic significance of dysadherin expression in cervical squamous cell carcinoma". Pathology Oncology Research. ج. 10 ع. 4: 212–8. DOI:10.1007/BF03033763. PMID:15619642.
- Nishizawa A، Nakanishi Y، Yoshimura K، Sasajima Y، Yamazaki N، Yamamoto A، Hanada K، Kanai Y، Hirohashi S (أبريل 2005). "Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma: immunohistochemical analysis of 115 patients". Cancer. ج. 103 ع. 8: 1693–700. DOI:10.1002/cncr.20984. PMID:15751018.
- Batistatou A، Scopa CD، Ravazoula P، Nakanishi Y، Peschos D، Agnantis NJ، Hirohashi S، Charalabopoulos KA (ديسمبر 2005). "Involvement of dysadherin and E-cadherin in the development of testicular tumours". British Journal of Cancer. ج. 93 ع. 12: 1382–7. DOI:10.1038/sj.bjc.6602880. PMC:2361540. PMID:16333245.
- Batistatou A، Makrydimas G، Zagorianakou N، Zagorianakou P، Nakanishi Y، Agnantis NJ، Hirohashi S، Charalabopoulos K (2007). "Expression of dysadherin and E-cadherin in trophoblastic tissue in normal and abnormal pregnancies". Placenta. ج. 28 ع. 5–6: 590–2. DOI:10.1016/j.placenta.2006.09.004. PMID:17084448.
- Batistatou A، Peschos D، Tsanou H، Charalabopoulos A، Nakanishi Y، Hirohashi S، Agnantis NJ، Charalabopoulos K (مايو 2007). "In breast carcinoma dysadherin expression is correlated with invasiveness but not with E-cadherin". British Journal of Cancer. ج. 96 ع. 9: 1404–8. DOI:10.1038/sj.bjc.6603743. PMC:2360179. PMID:17437014.
Content Disclaimer
Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.
- The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
- There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
- It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
- Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
- Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.
Index:
pl ar de en es fr it arz nl ja pt ceb sv uk vi war zh ru af ast az bg zh-min-nan bn be ca cs cy da et el eo eu fa gl ko hi hr id he ka la lv lt hu mk ms min no nn ce uz kk ro simple sk sl sr sh fi ta tt th tg azb tr ur zh-yue hy my ace als am an hyw ban bjn map-bms ba be-tarask bcl bpy bar bs br cv nv eml hif fo fy ga gd gu hak ha hsb io ig ilo ia ie os is jv kn ht ku ckb ky mrj lb lij li lmo mai mg ml zh-classical mr xmf mzn cdo mn nap new ne frr oc mhr or as pa pnb ps pms nds crh qu sa sah sco sq scn si sd szl su sw tl shn te bug vec vo wa wuu yi yo diq bat-smg zu lad kbd ang smn ab roa-rup frp arc gn av ay bh bi bo bxr cbk-zam co za dag ary se pdc dv dsb myv ext fur gv gag inh ki glk gan guw xal haw rw kbp pam csb kw km kv koi kg gom ks gcr lo lbe ltg lez nia ln jbo lg mt mi tw mwl mdf mnw nqo fj nah na nds-nl nrm nov om pi pag pap pfl pcd krc kaa ksh rm rue sm sat sc trv stq nso sn cu so srn kab roa-tara tet tpi to chr tum tk tyv udm ug vep fiu-vro vls wo xh zea ty ak bm ch ny ee ff got iu ik kl mad cr pih ami pwn pnt dz rmy rn sg st tn ss ti din chy ts kcg ve









